Alluvi, previously known as LY3414901, represents a noteworthy advancement in weight management. This combined-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receiver agonist exhibits remarkable efficacy in early trial data, with impressive weight lo